

# Integrated Risk Information System (IRIS) Program Public Science Meeting Topic #: Consideration of potential toxicity and toxicokinetic differences across vanadium compounds.

By Debbie C. Crans; Colorado State University

For developing *the Populations, Exposures, Comparators and Outcomes (PECO) criteria for Vanadium* with the ultimate goal of *setting guidelines for safe limits in drinking water*



## Disclaimer

- I do not have any financial relationships with persons or organizations having an interest in a toxicological review of vanadium compounds.
- No interested party had reviewed the input I am providing at the meeting today.

# **Topic: Consideration of potential toxicity and toxicokinetic differences across vanadium compounds.**

**By Debbie C. Crans; Colorado State University**

**For developing *the Populations, Exposures, Comparators and Outcomes (PECO) criteria for Vanadium* with the ultimate goal of *setting guidelines for safe limits in drinking water***

## **Vanadium levels in Blood and Plasma**

Vanadium salt interact with components in blood; proteins and metabolites

**Studies report recycling between oxidation states IV and V**

**Human study showing blood levels not consistent with observed response**

# Uptake depend on cell type/animal and vanadium compound

Cellular uptake difference between vanadyl(V) and vanadium(V(V))

- Model studies show different interactions and ability to penetrate interfaces / membranes

Answer:  $\text{NaVO}_3$  interact differently with the interface than  $\text{VOSO}_4$

- Animal cells show difference in toxic responses between  $\text{NaVO}_3$  and  $\text{VOSO}_4$

Answer: Generally  $\text{NaVO}_3$  slightly more toxic than  $\text{VOSO}_4$

- Human cells show difference in toxic responses between  $\text{NaVO}_3$  and  $\text{VOSO}_4$

Answer:  $\text{NaVO}_3$  slightly more toxic than  $\text{VOSO}_4$

Are differential effects of vanadium species observed in animal/human studies?

Answer: Sometimes yes / no – in animals and in humans – why?

- Vanadium(IV) salts given ad libitum can oxidize in the presence of oxygen
- The observations can be due to different species or overall concentrations

# **Topic: Consideration of potential toxicity and toxicokinetic differences across vanadium compounds.**

**Studies report recycling between oxidation states IV and V**

- **Both in vitro and in vivo studies demonstrate that interconversions do occur**


**Vanadium in blood / serum can be bound to blood / serum components**

- **Key blood/serum metabolites are glutathione and ascorbate**
- **Key blood/serum proteins are transferrin and serum albumin**
- **Extensive chemical work has been reported with these systems**

**Human study with Type 2 diabetic patients showing blood levels not consistent with observed response**


# Vanadium and glutathione

- Vanadium(V) and vanadium(IV) form both complexes with glutathione (GSH)
- Vanadium(IV) form complexes with glutathione (GSSG)
- Vanadium(V) can be reduced by GSH; metabolizing and can form both the V(IV)-GSH and V(IV)-GSSG complexes



The V(IV)<sup>2+</sup>-GSSG system V(IV) 7 mM and 70 mM GSSG


Pessoa et al. *J. Inor. Biochem.* 2001, 84, 259-270



The V(IV)O<sup>2+</sup>-GSH system with V(IV) 10 mM and 250 mM GSH


Pessoa et al. *J. Biol. Chem.* 2002, 7, 225-240

# Vanadium and Ascorbate



**Ascorbic acid**

- Vanadium for complexes with ascorbate
- Vanadium(V) is reduced by ascorbate
- The reaction contribute to convert any potential vanadium(V) compounds to vanadium(IV)



Scheme 1. Detailed mechanism for the ascorbic acid reduction by  $\text{VO}_2^+$  presented previously [14].

**Reaction supportive of the possibility that vanadium(V) complexes converts to vanadium(IV) in blood or plasma**

“Impairment of ascorbates’ anti-oxidant properties in confined media: Inter and intramolecular reactions with air and with vanadate at acidic pH,” Debbie C. Crans, Bharat Baruah, Ernestas Gaidamauskas, Brant G. Lemons and Michael D. Johnson, *J. Inorg. Biochem*, **2008**, *102*, 1334-1347 and references therein

# Vanadium and proteins in blood (transferrin and albumin)

- Vanadium in oxidation states III, IV and V are known to bind tightly to transferrin and transferred readily in blood
- Vanadium also is known to bind to serum albumin (both bovine and human serum albumin)
- Such interactions can be measured using MS methods

Very active research area:

D. Sanna, L. Biro, P. Buglyo, G. Micera and E. Garribba, *Metallomics*, **2012**, 4, 33–36.

J. C. Pessoa and I. Tomaz, *Curr. Med. Chem.*, 2010, 17, 3701–3738.

Recently reviewed in “Developing vanadium as an antidiabetic drug: A clinical and historical perspective” Debbie C. Crans, LaRee Henry, Gabriel Cardiff and Gary Posner, *Met. Ions Life Sci*, **2019**, 19, 203-230

Recent publications that may be of relevance

“Speciation of metal drugs, supplements and toxins in media and bodily fluids controls *in vitro* activities” Aviva Levina, Debbie C. Crans, Peter A. Lay *Coor. Chem. Rev.* **2017**, 352, 473-498.

“ESI-MS Study of the Interaction of Potential V<sup>IV</sup> Drugs and Amavadin with Proteins” Valeria Ugone, Daniele Sanna, Giuseppe Sciortino, Debbie C. Crans, and Eugenio Garribba *Inorg. Chem.* **2020**, 59, 9739-9755.

Levina and Lay *Inorg. Chem.* **2020**, ASAP


# Examination of administration of $\text{VO}_2\text{SO}_4$ to humans

*Type 2 diabetic patients were given 25, 50 or 100 mg  $\text{VO}_2\text{SO}_4$  3 times daily. Vanadium levels were measured using Graphite Furnace Atomic Absorption Spectroscopy*

*Figure Caption: Serum vanadium accumulation for all patients dosed at 25, 50, and 100 mg V as vanadyl sulfate. A one-compartment open model using the equation  $C_t = \text{baseline concentration} + C_0 e^{-kt}$ . Mean serum V levels are indicated by (•) for the 25 mg V dose, (▲) for the 50 mg V dose, and (■) for the 100 mg V dose.*

**Observation: Non-linear response between serum level and amount administered**

**Conclusion: The total vanadium pool is not the active pool of vanadium**



“Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients,” Gail R. Willsky, Katherine Halvorson, Michael E. Godzala III, Lai-Har Chi, Mathew Most, Peter Kaszynski, Debbie C. Crans, Allison B. Goldfine and Paul J. Kostnyniak, *Metallomics*, **2013**, 5, (11) 1491-1502.

# **Topic: Consideration of potential toxicity and toxicokinetic differences across vanadium compounds.**

## **Take home messages:**

### **Vanadium levels in Blood and Plasma**

- Uptake depend on speciation and should be measured**
- Interaction with the membrane exist and several uptake mechanisms documented**

### **Are differential effects of vanadium species observed?**

- Yes studies have been reported with both diabetic animals and human beings**
- Some of these effects are due to different vanadium compounds but in the case of salts may also be due to overall concentrations**

# **Topic: Consideration of potential toxicity and toxicokinetic differences across vanadium compounds.**

## **Take home messages:**

**Presence in blood / serum depend on blood / serum components**

- Blood Components: glutathione, ascorbate, transferrin and serum albumin all bind vanadium and can be measured**
- Presence in blood may change as a function of time; more data is needed on changes as a function of time**
- Method has now been reported to measure the protein-vanadium complexes**

**Study with human Type 2 diabetic patients showing vanadium blood and serum levels did not correlate with the observed antidiabetic effects**